Literature DB >> 15661738

The human TREX2 3' -> 5'-exonuclease structure suggests a mechanism for efficient nonprocessive DNA catalysis.

Fred W Perrino1, Scott Harvey, Sara McMillin, Thomas Hollis.   

Abstract

The 3' --> 5'-exonucleases process DNA ends in many DNA repair pathways of human cells. Determination of the human TREX2 structure is the first of a dimeric 3'-deoxyribonuclease and indicates how this highly efficient nonprocessive enzyme removes nucleotides at DNA 3' termini. Symmetry in the TREX2 dimer positions the active sites at opposite outer edges providing open access for the DNA. Adjacent to each active site is a flexible region containing three arginines positioned appropriately to bind DNA and to control its entry into the active site. Mutation of these three arginines to alanines reduces the DNA binding capacity by approximately 100-fold with no effect on catalysis. The human TREX2 catalytic residues overlay with the bacterial DnaQ family of 3'-exonucleases confirming the structural conservation of the catalytic sites despite limited sequence identity, and mutations of these residues decrease the still measurable activity by approximately 10(5)-fold, confirming their catalytic role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661738     DOI: 10.1074/jbc.M500108200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Authors:  Clinton D Orebaugh; Jason M Fye; Scott Harvey; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.

Authors:  Suzanna L Bailey; Scott Harvey; Fred W Perrino; Thomas Hollis
Journal:  DNA Repair (Amst)       Date:  2011-11-08

3.  Aromatic residues in RNase T stack with nucleobases to guide the sequence-specific recognition and cleavage of nucleic acids.

Authors:  Yulander Duh; Yu-Yuan Hsiao; Chia-Lung Li; Jason C Huang; Hanna S Yuan
Journal:  Protein Sci       Date:  2015-09-18       Impact factor: 6.725

4.  Structure of the Escherichia coli DNA polymerase III epsilon-HOT proofreading complex.

Authors:  Thomas W Kirby; Scott Harvey; Eugene F DeRose; Sergey Chalov; Anna K Chikova; Fred W Perrino; Roel M Schaaper; Robert E London; Lars C Pedersen
Journal:  J Biol Chem       Date:  2006-09-13       Impact factor: 5.157

5.  WRN exonuclease activity is blocked by DNA termini harboring 3' obstructive groups.

Authors:  Jeanine A Harrigan; Jinshui Fan; Jamil Momand; Fred W Perrino; Vilhelm A Bohr; David M Wilson
Journal:  Mech Ageing Dev       Date:  2006-12-20       Impact factor: 5.432

6.  A universal fluorescence-based toolkit for real-time quantification of DNA and RNA nuclease activity.

Authors:  Emily C Sheppard; Sally Rogers; Nicholas J Harmer; Richard Chahwan
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

7.  The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.

Authors:  Duane A Lehtinen; Scott Harvey; Matthew J Mulcahy; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

8.  Measuring TREX1 and TREX2 exonuclease activities.

Authors:  Wayne O Hemphill; Fred W Perrino
Journal:  Methods Enzymol       Date:  2019-06-08       Impact factor: 1.600

9.  Crystal structure of CRN-4: implications for domain function in apoptotic DNA degradation.

Authors:  Yu-Yuan Hsiao; Akihisa Nakagawa; Zhonghao Shi; Shohei Mitani; Ding Xue; Hanna S Yuan
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

10.  Limiting the persistence of a chromosome break diminishes its mutagenic potential.

Authors:  Nicole Bennardo; Amanda Gunn; Anita Cheng; Paul Hasty; Jeremy M Stark
Journal:  PLoS Genet       Date:  2009-10-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.